Previous 10 | Next 10 |
home / stock / blu:cc / blu:cc news
S&P Dow Jones Indices Announces Changes to the S&P/TSX Composite Index and S&P/TSX 60 Index S&P Dow Jones Indices Announces Changes to the S&P/TSX Composite Index and S&P/TSX 60 Index Canada NewsWire TORONTO , Sept. 2, 2022 /CN...
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indicati...
- Completed positive End-of-Phase 2 meeting with the Food and Drug Administration (“FDA”) and received scientific advice from the European Medicines Agency (“EMA”) to support design of its CALM Phase 3 program, which is expected to initiate in Q4 2022 -...
A lot of people do not like investing with limited capital. They stockpile their savings until they have a sizeable enough sum to invest with. But whatever savings you keep as cash are vulnerable to inflation — the silent tax that devalues your wealth kept in cash. One way to ensure ...
BELLUS Health Inc. (NASDAQ: BLU)(TSX: BLU) (the “Company” or “BELLUS Health”) announced today that it has completed its previously-announced underwritten public offering in Canada and the United States (the “Offering”) of 16,540,541 common share...
Common Shares Priced at US$9.25 per Share In connection with its previously announced public offering of common shares in Canada and the United States (the “Offering”), BELLUS Health Inc. (“BELLUS Health” or the “Company”) (TSX a...
BELLUS Health Inc. (“BELLUS Health” or the “Company”) (TSX and Nasdaq: BLU), announced today the filing of a preliminary prospectus supplement (the “Supplement”) to its amended and restated short form base shelf prospectus dated December 14, 202...
- CALM Phase 3 program consists of two pivotal trials (CALM-1 and CALM-2), with primary efficacy endpoint of 24-hour cough frequency measured at 12- and 24-weeks, respectively - - The Company has reached alignment with FDA on the primary efficacy endpoint of 24H cough frequenc...
The current market-wide slump has pushed down a lot of stocks, negating a significant portion of the growth they accumulated since the 2020 crash. However, there are plenty of companies that have managed to remain profitable in 2022, and if you had invested in them at the beginning of the y...
Rising interest rates affect businesses — more so for growth-oriented companies. Technology is the hardest-hit sector in an inflationary period, as tech companies rely on borrowing to pursue growth initiatives. However, there are exceptions. Some companies — not only in tech b...
News, Short Squeeze, Breakout and More Instantly...
Stock-exchange announcement - For media and investors only - GSK completes acquisition of BELLUS Health Canada NewsWire LONDON , June 28, 2023 /CNW/ - GSK plc (LSE: GSK) (NYSE: GSK) and BELLUS Health Inc. (TSX: BLU) NASDAQ: BLU) today announced GSK has completed ...
2023-06-27 18:45:00 ET Early investors in Canadian biotech stock BELLUS Health ( TSX:BLU ) could be ecstatic right now after a fine 75.5% rally in BLU stock year to date. The bullish run was ensued after global pharmaceuticals giant GSK offered to acquire all BELLUS stock at...
BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU.TO) (“ BELLUS ” or the “ Company ”) today announced the positive outcome of the BELLUS shareholders (“ Shareholders ”) vote at this morning’s special meeting of the Shareholders (the “ ...